{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:24:46Z","timestamp":1790835886881,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ctrv.2025.103000","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:55:14Z","timestamp":1753458914000},"page":"103000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The emerging role of PARP inhibitors in prostate cancer: A narrative review"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-2837","authenticated-orcid":false,"given":"Lorenzo","family":"Lobianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Calvanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"D\u2019Ausilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena Di","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristin","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella De","family":"Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Lamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103000_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2025.103000_b0010","article-title":"An In-depth look into the epidemiological and etiological aspects of prostate cancer: a literature review","volume":"15","author":"Al-Ghazawi","year":"2023","journal-title":"Cureus."},{"key":"10.1016\/j.ctrv.2025.103000_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(94)80237-8","article-title":"Observations on the epidemiology and natural history of prostate cancer","volume":"44","author":"Montie","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2025.103000_b0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrurol.2013.266","article-title":"The genetic epidemiology of prostate cancer and its clinical implications","volume":"11","author":"Eeles","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ctrv.2025.103000_b0025","doi-asserted-by":"crossref","first-page":"470","DOI":"10.20892\/j.issn.2095-3941.2020.0481","article-title":"BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees","volume":"18","author":"Cortesi","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2025.103000_b0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2025.103000_b0035","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103000_b0045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103000_b0050","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/cancers15092435","article-title":"Frequency of germline and somatic BRCA1 and BRCA2 mutations in prostate cancer: an updated systematic review and meta-analysis","volume":"15","author":"Valsecchi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2025.103000_b0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/jpm14030287","article-title":"The application of radiomics and AI to molecular imaging for prostate cancer","volume":"14","author":"Tapper","year":"2024","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/j.ctrv.2025.103000_b0060","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103000_b0075","article-title":"Targeting DNA damage and Repair (DDR) pathways: advances in Understanding and Therapeutic Implications","volume":"9","author":"Rashid","year":"2024","journal-title":"Clinics in Oncology"},{"key":"10.1016\/j.ctrv.2025.103000_b0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yexcr.2014.08.027","article-title":"DNA single-strand break repair","volume":"329","author":"Caldecott","year":"2014","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1115241","article-title":"DNA repair deficiency as circulating biomarker in prostate cancer","volume":"13","author":"Catalano","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cr.2008.8","article-title":"Early steps in the DNA base excision\/single-strand interruption repair pathway in mammalian cells","volume":"18","author":"Hegde","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0095","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ctrv.2025.103000_b0100","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2025.103000_b0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.103000_b0110","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2025.103000_b0115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.tig.2021.03.001","article-title":"Nonhomologous end joining: new accessory factors fine tune the machinery","volume":"37","author":"Ghosh","year":"2021","journal-title":"Trends Genet"},{"key":"10.1016\/j.ctrv.2025.103000_b0120","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jmcb\/mjq055","article-title":"BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability","volume":"3","author":"Aly","year":"2011","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2025.103000_b0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"endocr Rev"},{"key":"10.1016\/j.ctrv.2025.103000_b0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2020.12.007","article-title":"Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development","volume":"73","author":"Font-D\u00edaz","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ctrv.2025.103000_b0140","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A Hormone\u2013DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103000_b0145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103000_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor\u2013induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.ctrv.2025.103000_b0155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103000_b0160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-024-02071-y","article-title":"Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"84","author":"Kostos","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2025.103000_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103000_b0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-0716-2891-1_19","article-title":"Examining the effect of PARP-1 inhibitors on transcriptional activity of androgen receptor in prostate cancer cells","volume":"2609","author":"Makhov","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ctrv.2025.103000_b0175","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1093\/nar\/gkz286","article-title":"A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities","volume":"47","author":"Kounatidou","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 inhibition: preclinical and phase 1 evaluation in patients with advanced solid tumours","volume":"126","author":"Konstantinopoulos","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2025.103000_b0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y","article-title":"Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer","volume":"25","author":"Hyytinen","year":"1999","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.ctrv.2025.103000_b0190","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1172\/JCI44239","article-title":"The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression","volume":"120","author":"Sharma","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2025.103000_b0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2025.103000_b0200","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/1078-0432.CCR-19-1570","article-title":"Significance of BRCA2 and RB1 Co-loss in aggressive prostate cancer progression","volume":"26","author":"Chakraborty","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0210","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.3390\/ijms23094786","article-title":"Androgen receptor gene pathway upregulation and radiation resistance in oligometastatic prostate cancer","volume":"23","author":"Saxby","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103000_b0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/JCO.2019.37.7_suppl.35","article-title":"A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) \u00b1 degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03","volume":"37","author":"Pacey","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0220","doi-asserted-by":"crossref","first-page":"B061","DOI":"10.1158\/1538-7445.PRCA2023-B061","article-title":"Abstract B061: Updated analysis of \u201cCANCAP03\u201d \u2013 a study into the pharmacodynamic biomarker effects of olaparib (PARP inhibitor) \u00b1 degarelix (GnRH antagonist) given prior to radical prostatectomy","volume":"83","author":"Dev","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0225","article-title":"Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): a single-arm phase 2 study","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2025.103000_b0230","unstructured":"Gleave, M. Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer. https:\/\/clinicaltrials.gov\/study\/NCT04812366 (2024)."},{"key":"10.1016\/j.ctrv.2025.103000_b0235","article-title":"Neo-adjuvant PARP inhibition prior to prostatectomy: a phase II biomarker-driven trial for men with high-risk, localized prostate cancer and alterations in DNA repair genes","volume":"41","author":"Dall\u2019era","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0240","unstructured":"Brown University. BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes. https:\/\/clinicaltrials.gov\/study\/NCT03432897 (2022)."},{"key":"10.1016\/j.ctrv.2025.103000_b0245","doi-asserted-by":"crossref","unstructured":"McKay, R. A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune). https:\/\/clinicaltrials.gov\/study\/NCT05498272 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5128"},{"key":"10.1016\/j.ctrv.2025.103000_b0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103000_b0255","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.3390\/ijms241612978","article-title":"Parp Inhibitors and Radiotherapy: a New Combination for Prostate Cancer (Systematic Review)","volume":"24","author":"Rivero Belench\u00f3n","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103000_b0260","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/j.annonc.2020.08.2083","article-title":"689TiP NRG Oncology\u2019s GU007 (NADIR): a randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)","volume":"31","author":"Zumsteg","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0265","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2025.103000_b0270","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic Value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103000_b0285","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1200\/JCO.2019.37.15_suppl.5045","article-title":"Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis","volume":"37","author":"Antonarakis","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0290","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","article-title":"Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial","volume":"10","author":"Marshall","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0275","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/oncolo\/oyae030","article-title":"A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer demonstrating \u201cBRCAness\u201d genotype (ROAR)","volume":"29","author":"Sahu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.103000_b0280","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2023.41.6_suppl.364","article-title":"A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with \u201cBCRAness\u201d genotype (ROAR)","volume":"41","author":"Sahu","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0300","unstructured":"Memorial Sloan Kettering Cancer Center. A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair. https:\/\/clinicaltrials.gov\/study\/NCT03810105 (2024)."},{"key":"10.1016\/j.ctrv.2025.103000_b0305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.36401\/JIPO-24-36","article-title":"Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer","volume":"8","author":"Autio","year":"2025","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0295","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.3390\/ijms23063238","article-title":"Targeting DNA damage response and immune checkpoint for anticancer therapy","volume":"23","author":"Huang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103000_b0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0315","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/oncolo\/oyae120","article-title":"TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations","volume":"29","author":"Markowski","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2025.103000_b0320","doi-asserted-by":"crossref","first-page":"S966","DOI":"10.1016\/j.annonc.2024.08.1682","article-title":"1601P first results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-na\u00efve prostate cancer (mHNPC)","volume":"35","author":"Mateo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0325","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.9","volume":"39","author":"Rathkopf","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","article-title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","author":"Attard","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0330","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0335","volume":"42","author":"Chi","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0345","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/biomedicines10030689","article-title":"Definition of castrate resistant prostate cancer: new insights","volume":"10","author":"Morote","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2025.103000_b0350","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103000_b0355","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0360","doi-asserted-by":"crossref","first-page":"v884","DOI":"10.1093\/annonc\/mdz394.043","article-title":"LBA50 - Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)","volume":"30","author":"Smith","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0365","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0370","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy284.002","article-title":"Preliminary results from TRITON2: a phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations","volume":"29","author":"Abida","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0375","doi-asserted-by":"crossref","first-page":"v327","DOI":"10.1093\/annonc\/mdz248.003","article-title":"Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses","volume":"30","author":"Abida","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0380","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the Treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103000_b0385","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0390","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0395","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103000_b0400","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.2025.43.5_suppl.155","article-title":"Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety","volume":"43","author":"Bryce","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0405","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.ctrv.2025.103000_b0430","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0410","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial\u2606","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0415","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103000_b0435","doi-asserted-by":"crossref","first-page":"LBA18","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0440","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2025.43.16_suppl.5019","article-title":"Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2","volume":"43","author":"Zschaebitz","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0420","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2022.40.16_suppl.5018","article-title":"BRCAAWAY: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects","volume":"40","author":"Hussain","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0445","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm)","volume":"42","author":"Hussain","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5107","article-title":"Alliance A031902 (CASPAR): a randomized, phase (ph) 3 trial of enzalutamide with rucaparib\/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)","author":"Rao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0450","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2023.41.6_suppl.196","article-title":"Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC)","volume":"41","author":"Pili\u00e9","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 Gene alteration","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0455","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2025.43.16_suppl.5008","article-title":"C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +\/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC)","volume":"43","author":"Aparicio","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0470","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort a study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103000_b0475","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103000_b0480","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004761","article-title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","volume":"10","author":"Fizazi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103000_b0490","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab Plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 Trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0485","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab Plus Talazoparib in patients with Advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0500","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-22-0583","article-title":"A phase I Study of Combination Olaparib and Radium-223 in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)","volume":"22","author":"Pan","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.103000_b0510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5007","article-title":"A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): initial efficacy and biomarker analysis","author":"McKay","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0495","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0505","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-22-2526","article-title":"Phase I study of Niraparib in combination with radium-223 for the treatment of metastatic castrate resistant prostate cancer","volume":"29","author":"Quinn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0515","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized Trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results from national cancer institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103000_b0520","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-22-2585","article-title":"A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Pook","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0525","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2022.40.6_suppl.088","article-title":"Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial)","volume":"40","author":"Reichert","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103000_b0460","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103000_b0465","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.3390\/ijerph19148577","article-title":"Recent Insights into PARP and Immuno-checkpoint inhibitors in epithelial ovarian cancer","volume":"19","author":"Revythis","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ctrv.2025.103000_b0530","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ijms26020802","article-title":"Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response","volume":"26","author":"Hamid","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:52:43Z","timestamp":1762015963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":105,"alternative-id":["S0305737225001227"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103000","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of PARP inhibitors in prostate cancer: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103000"}}